drugset / Trial / NCT04415320
X-396 (Ensartinib) Capsules in ALK-Positive NSCLC Patients With Brain Metastases
NaSingle-groupOpen-labelTreatment
Summary
To assess efficacy and safety of oral X-396 (Ensartinib) capsule in Chinese ALK-positive NSCLC patients with brain metastases, eligible patients will be enrolled with objective responses being primary outcome measures.
Timeline
- Start
- 2019-03-21
- Primary completion
- 2020-12
- Completion
- 2021-06
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Ensartinib | Small molecule | 225 mg | Oral |